Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor
mBio · 2024
DOI: 10.1128/mbio.00741-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Najing Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Cen…. Hauptthemen laut MEDLINE: Antiviral Agents, Influenza A virus, SARS-CoV-2, Virus Internalization. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), MOST | National Key Research and Development Program of China (NKPs).
Abstract (Originalsprache)
Outbreaks of acute respiratory viral diseases, such as influenza and COVID-19 caused by influenza A virus (IAV) and SARS-CoV-2, pose a serious threat to global public health, economic security, and social stability. This calls for the development of broad-spectrum antivirals to prevent or treat infection or co-infection of IAV and SARS-CoV-2. Hemagglutinin (HA) on IAV and spike (S) protein on SARS-CoV-2, which contain various types of glycans, play crucial roles in mediating viral entry into host cells. Therefore, they are key targets for the development of carbohydrate-binding protein-based antivirals. This study demonstrated that griffithsin (GRFT) and the GRFT-based bivalent entry inhibitor GL25E (GRFT-L25-EK1) showed broad-spectrum antiviral effects against IAV infection in vitro by binding to HA in a carbohydrate-dependent manner and effectively protected mice from lethal IAV infection. Although both GRFT and GL25E could inhibit infection of SARS-CoV-2 Omicron variants, GL25E proved to be significantly more effective than GRFT and EK1 alone. Furthermore, GL25E effectively inhibited in vitro co-infection of IAV and SARS-CoV-2 and demonstrated good druggability, including favorable safety and stability profiles. These findings suggest that GL25E is a promising candidate for further development as a broad-spectrum antiviral drug for the prevention and treatment of infection or co-infection from IAV and SARS-CoV-2. IMPORTANCE Influenza and COVID-19 are highly contagious respiratory illnesses caused by the influenza A virus (IAV) and SARS-CoV-2, respectively. IAV and SARS-CoV-2 co-infection exacerbates damage to lung tissue and leads to more severe clinical symptoms, thus calling for the development of broad-spectrum antivirals for combating IAV and SARS-CoV-2 infection or co-infection. Here we found that griffithsin (GRFT), a carbohydrate-binding protein, and GL25E, a recombinant protein consisting of GRFT, a 25 amino acid linker, and EK1, a broad-spectrum coronavirus inhibitor, could effectively inhibit IAV and SARS-CoV-2 infection and co-infection by targeting glycans on HA of IAV and spike (S) protein of SARS-CoV-2. GL25E is more effective than GRFT because GL25E can also interact with the HR1 domain in SARS-CoV-2 S protein. Furthermore, GL25E possesses favorable safety and stability profiles, suggesting that it is a promising candidate for development as a drug to prevent and treat IAV and SARS-CoV-2 infection or co-infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medica…
- Guiyang Maternal and Child Health Care Hospital, Guiyang, Guizhou, China.
ORCID-Profile: Najing Cao, Lu Lu, Shibo Jiang, Wei Xu
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- MOST | National Key Research and Development Program of China (NKPs)
Zitieren
APA
Cao, N., Cai, Y., Huang, X., Jiang, H., Huang, Z., Xing, L., Lu, L., Jiang, S., & Xu, W. (2024). Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor. mBio. https://doi.org/10.1128/mbio.00741-24
Vancouver
Cao N, Cai Y, Huang X, Jiang H, Huang Z, Xing L, et al. Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor. mBio. 2024. doi:10.1128/mbio.00741-24
BibTeX
@article{Cao2024,
author = {Cao, Najing and Cai, Yanxing and Huang, Xin and Jiang, Hanxiao and Huang, Ziqi and Xing, Lixiao and Lu, Lu and Jiang, Shibo and Xu, Wei},
title = {Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor},
journal = {mBio},
year = {2024},
doi = {10.1128/mbio.00741-24}
}
EUVIMED